Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 24;8(7):1290-1300.
doi: 10.1016/j.ekir.2023.04.016. eCollection 2023 Jul.

Managing Hyperkalemia in the Modern Era: A Case-Based Approach

David Massicotte-Azarniouch  1   2 , Mark Canney  1   2 , Manish M Sood  1   2 , Gregory L Hundemer  1   2
Affiliations
Review

Managing Hyperkalemia in the Modern Era: A Case-Based Approach

David Massicotte-Azarniouch et al. Kidney Int Rep. .

Abstract

The last decade has seen tremendous advances in the prevention and treatment of recurrent hyperkalemia. In this narrative review, we aim to highlight contemporary data on key areas in the epidemiology and management of hyperkalemia. Focusing on drug-induced hyperkalemia (the implications of renin-angiotensin-aldosterone system inhibitors [RAASi] discontinuation and the role of mineralocorticoid receptor antagonists), newer concurrent therapies that modify potassium handling (sodium-glucose transporter 2 inhibitors [SGLT2i]), the introduction of new treatment agents (oral potassium binding agents), and the controversial role of dietary potassium restriction, we apply recent research findings and review the evidence in a case-based format.

Keywords: dietary potassium; diuretics; hyperkalemia; novel potassium binders; renin-angiotensin-aldosterone inhibitors (RAAS inhibitors); sodium-glucose transporter 2 inhibitors (SGLT2 inhibitors).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of pros and cons of various management options for outpatient hyperkalemia. RAASi, renin-angiotensin-aldosterone system inhibitors; SGLT2i, sodium-glucose transporter 2 inhibitors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Dépret F., Peacock W.F., Liu K.D., Rafique Z., Rossignol P., Legrand M. Management of hyperkalemia in the acutely ill patient. Ann Intensive Care. 2019;9:32. doi: 10.1186/s13613-019-0509-8. - DOI - PMC - PubMed
    1. Lemoine L., Le Bastard Q., Batard E., Montassier E. An evidence-based narrative review of the emergency department management of acute hyperkalemia. J Emerg Med. 2021;60:599–606. doi: 10.1016/j.jemermed.2020.11.028. - DOI - PubMed
    1. Don B.R., Sebastian A., Cheitlin M., Christiansen M., Schambelan M. Pseudohyperkalemia caused by fist clenching during phlebotomy. N Engl J Med. 1990;322:1290–1292. doi: 10.1056/nejm199005033221806. - DOI - PubMed
    1. Wiederkehr M.R., Moe O.W. Factitious hyperkalemia. Am J Kidney Dis. 2000;36:1049–1053. doi: 10.1053/ajkd.2000.19084. - DOI - PubMed
    1. Graber M., Subramani K., Corish D., Schwab A. Thrombocytosis elevates serum potassium. Am J Kidney Dis. 1988;12:116–120. doi: 10.1016/s0272-6386(88)80005-2. - DOI - PubMed

LinkOut - more resources